“China’s ANMAT-approved Dengue vaccine now available for Misiones province in Argentina”

The inoculant manufactured in China was tested and approved by the ANMAT. The Minister of Public Health of the province explained that in Misiones “the decrease in cases is noticeable.”

In recent days it was learned that the National Administration of Medicines, Food and Medical Technology (ANMAT) carried out the necessary tests for the approval of the dengue vaccine. The doses are manufactured by the Chinese laboratory Takeda. Misiones is one of the provinces that functioned as a wall against the disease. The greatest complexity of the red land is delimiting with endemic countries such as Brazil and Paraguay.

Public Health Minister Oscar Alarcón explained that “it is something historic for this stage of the year, where we were used to only some specific provinces suffering from it,” he said. He also stated that the reality in Misiones is very different with marked decreases in cases.

“If we look at the map of cases, the red dots are in Brazil and Paraguay. And if we look at the country, most of them occur in other provinces far from Misiones”, explained the head of the health portfolio for the people affected in the center of the national territory.

“We did not have any deaths of the 56 produced in Argentina by the disease, nor serious hospitalizations. I think it is the product of the actions that were carried out between the municipalities, Public Health, NGOs, security forces and the citizens who understood that after the gate, the responsibility belongs to each one with the cleaning tasks ”, he related.

dengue vaccine

The drug was recently approved by the National Administration of Medicines, Food and Medical Technology (ANMAT). It was developed by the Japanese laboratory Takeda for all people over 4 years of age, whether or not they have previously had the disease. Its form of administration consists of two doses that must be applied at an interval of three months.

After approval, the laboratory will establish the protocols for the start of the production process to send a batch of it to the country. When this happens, once this cycle is completed and always following quality and traceability standards, Argentina will be in a position to receive this shipment for its subsequent commercialization in national territory.

In this line, Alarcón expressed that the vaccine is indicated -in the first instance- for endemic areas where the presence of dengue is permanent, and that in the coming days there will be more certainty of what the arrival process will be like.

He pointed out that “the good thing is that winter is coming and we will have rest in terms of cases, but we will continue to monitor permanently. Today we can say that we are on an epidemiological ‘honeymoon’ and that the concern is not to run out and vaccinate, but to wait for all the certainties that must be given so that it is a safe drug for people”.

He assured that this process will take place “much sooner” than next year. “The meetings are taking place and the vaccine is approved, what has not yet been done is the first batch and delivery to the country.”

Source: Codes magazine